HGFR/c-MET Products

Description

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Bioinformatics

Entrez	17295 Mouse 24553 Rat 4233 Human
Uniprot	NM_000245 Human NM_000245.2 Human NP_000236 Human NP_001120972 Human P08581 Human
Product By Gene ID	4233
Alternate Names	AUTS9 c-Met EC 2.7.10 EC 2.7.10.1 hepatocyte growth factor receptor HGF receptor HGF/SF receptor HGFR Met (c-Met) met proto-oncogene (hepatocyte growth factor receptor) met proto-oncogene tyrosine kinase oncogene MET Proto-oncogene c-Met RCCP2 Scatter factor receptor SF receptor Tyrosine-protein kinase Met

Research Areas for HGFR/c-MET

Find related products by research area and learn more about each of the different research areas below.

Cancer
Cell Cycle and Replication
Cellular Markers
Phospho-Specific
Protein Kinase
Signal Transduction
Tyrosine Kinases